{"id":"sbr759a","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Diarrhea"},{"rate":"15-25%","effect":"Nausea"},{"rate":"10-20%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"SBR759A works by inhibiting the PI3K enzyme, which is involved in cell signaling and proliferation. This inhibition can lead to anti-tumor effects in various types of cancer.","oneSentence":"SBR759A is a small molecule that targets the PI3K pathway.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:33:44.189Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer"},{"name":"Metastatic colorectal cancer"}]},"trialDetails":[{"nctId":"NCT01069692","phase":"PHASE3","title":"Placebo Versus SBR759 in Lowering Phosphate in Dialysis Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-02","conditions":"Hyperphosphatemia, Chronic Kidney Disease","enrollment":115}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SBR759A","genericName":"SBR759A","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SBR759A is a small molecule that targets the PI3K pathway. Used for Metastatic breast cancer, Metastatic colorectal cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}